Prev Close | 7.42 |
Open | 7.51 |
Day Low/High | 7.41 / 7.78 |
52 Wk Low/High | 5.91 / 12.63 |
Volume | 2.21M |
Prev Close | 7.42 |
Open | 7.51 |
Day Low/High | 7.41 / 7.78 |
52 Wk Low/High | 5.91 / 12.63 |
Volume | 2.21M |
Exchange | NASDAQ |
Shares Outstanding | 280.16B |
Market Cap | 2.04B |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
I've stayed primarily to those names that have plenty of cash on the balance sheet and should be just fine once saner heads prevail.
Both these names reported third-quarter results last week.
These small biotech concerns are undervalued.
The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
The names include a veterinary drug concern plus companies with successful drugs on the market.
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
The combination of three charts gives me a bullish view on FOLD.
Despite the January rally, this biotech name and building materials firm still have further to rise.
Other than the Dow, most of major market indices are showing small gains heading into the last hour of trading. The biotech sector has not participated in today's rally and is down some 0.75% on the day so far. I am watching a few small biotech and ...
I think M&A activity will pick up markedly going forward across the industry.
Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...
Outside of oncology, the rare disease area is a good target for M&A in 2018.
Outside of oncology, the rare disease area is a good target for M&A in 2018.
Markets have weakened over the past hour. There has been a very narrow trading range so far today. Biotech continued to strengthen. I think the sector is gaining a bit of strength as some small caps like Amicus Therapeutics present at the JP Morgan...
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.
The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.
So I'm staying focused on stock picking.
It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.
Apple and its suppliers are dragging the market down.
Shares of this biotech look ready for further strong gains.
The market is maintaining slight gains across the board as we approach the noon hour. Lodging REITS are strong today on the back of the news that RLJ Lodging Trust has received a competing buyout offer from a PE firm for $24 a share. Shares are up ...
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.
Three small-cap biotechs with attractive risk/reward profiles.
M&A, drug approvals and Trump are all on my watch list.